Table 1.
Demographic and clinical characteristics of study cohort.
| Total (N) | R (n) | NR (n) | p | |
|---|---|---|---|---|
| BL | 72 | 44 | 28 | |
| Age, years (M ± SD) | 50.0 ± 15.3 | 58.2 ± 14.3 | 52.5 ± 16.5 | 0.126 |
| Female (%) | 39 (54.1%) | 26 (59.1%) | 13 (46.4%) | 0.293 |
| Male (%) | 33 (45.9%) | 18 (40.9%) | 15 (53.6%) | |
| IOP1, mmHg (M ± SD) | 24.3 ± 2.9 | 24.8 ± 3.2 | 23.4 ± 2.1 | 0.063 |
| IOP2, mmHg (M ± SD) | 19.0 ± 3.1 | 17.2 ± 2.3 | 21.6 ± 2.4 | 0.0001 |
| BCVA (M ± SD) | 0.88 ± 0.25 | 0.92 ± 0.24 | 0.83 ± 0.26 | 0.161 |
| PG | 80 | 45 | 35 | |
| Age, years (M ± SD) | 57.8 ± 13.4 | 57.6 ± 13.6 | 57.9 ± 13.4 | 0.914 |
| Female (%) | 43 (54%) | 23 (51%) | 20 (57%) | 0.447 |
| Male (%) | 37 (46%) | 22 (49%) | 15 (43%) | |
| IOP1, mmHg (M ± SD) | 24.4 ± 2.2 | 24.6 ± 3.7 | 24.3 ± 3.1 | 0.701 |
| IOP2, mmHg (M ± SD) | 18.9 ± 3.3 | 16.8 ± 2.5 | 21.3 ± 3.1 | 0.0001 |
| BCVA (M ± SD) | 0.90 ± 0.29 | 0.99 ± 0.21 | 0.80 ± 0.34 | 0.006 |
BL, beta-blocker (timolol maleate) treatment group; PG, prostaglandin analogue (latanoprost) treatment group; R, responder individuals; NR, non-responder individuals; (N)(n), number of individuals; IOP1, intraocular pressure before treatment; IOP2, after treatment; BCVA, best corrected visual acuity (decimal); M ± SD, mean ± standard deviation; p, p-value for responders vs non-responders.